What are the best outpatient oral antibiotics for treating an uncomplicated infected wound?

Best Outpatient Oral Antibiotics for Infected Wounds

For uncomplicated infected wounds in outpatients, the choice depends on whether the infection is purulent or nonpurulent: for purulent infections (with drainage/exudate), use clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or doxycycline to cover community-acquired MRSA; for nonpurulent cellulitis, use cephalexin, dicloxacillin, or amoxicillin-clavulanate to cover streptococci and methicillin-sensitive staph aureus. 1

Clinical Decision Algorithm

Step 1: Classify the Wound Infection Type

Purulent infection (has pus, drainage, or exudate):

• Empirically cover for CA-MRSA, which now causes the majority of skin infections 1
• Streptococcal coverage is likely unnecessary 1

Nonpurulent cellulitis (no drainage, no abscess):

• Empirically cover for β-hemolytic streptococci 1
• Add MRSA coverage only if patient fails β-lactam therapy or has systemic toxicity 1

Step 2: Select Appropriate Antibiotic

For Purulent Infections (MRSA coverage needed):

First-line options 1:

• Clindamycin 300-450 mg PO three times daily (A-II evidence)

  • Advantage: Also covers streptococci, so monotherapy works
  • Caution: Check local resistance rates; avoid if >10% inducible clindamycin resistance 1

• TMP-SMX 1-2 double-strength tablets twice daily (A-II evidence)

  • Must add amoxicillin 500 mg three times daily if streptococcal coverage needed 1
  • Does NOT cover streptococci alone

• Doxycycline 100 mg twice daily (A-II evidence)

  • Must add amoxicillin if streptococcal coverage needed 1
  • Avoid in children <8 years and pregnant women 1

• Linezolid 600 mg twice daily (A-II evidence)

  • Covers both MRSA and streptococci as monotherapy 1
  • Expensive; reserve for resistant cases or treatment failures

For Nonpurulent Cellulitis (Streptococcal coverage):

First-line options 2, 3:

• Cephalexin 500 mg four times daily (A-II evidence)
• Dicloxacillin 500 mg four times daily (A-II evidence)
• Amoxicillin-clavulanate 875/125 mg twice daily (A-II evidence)

Step 3: Duration of Therapy

• 5-10 days for most uncomplicated infections 1
• Individualize based on clinical response—continue until infection resolves, not necessarily until wound heals 2
• For mild infections: 1-2 weeks usually sufficient 2

Step 4: When to Add MRSA Coverage to Nonpurulent Cellulitis

Add empiric MRSA coverage if 1:

• Patient fails initial β-lactam therapy after 48-72 hours
• Signs of systemic toxicity present
• Known MRSA colonization
• Recent antibiotic use
• High local MRSA prevalence

Critical Considerations for Specific Wound Types

Diabetic foot infections (mild) 2, 4:

• Dicloxacillin, cephalexin, or amoxicillin-clavulanate for mild infections
• If MRSA suspected: TMP-SMX
• These often require 2-4 weeks of therapy 2

Surgical/traumatic wounds 1:

• If complicated or deep: consider broader coverage initially
• Simple superficial wounds: treat as purulent vs nonpurulent above

Animal/human bites 5:

• Amoxicillin-clavulanate 875/125 mg twice daily is drug of choice
• Covers polymicrobial flora including anaerobes and Pasteurella

Common Pitfalls to Avoid

1. Don't use TMP-SMX or doxycycline alone for nonpurulent cellulitis—they lack streptococcal coverage and strep is the primary pathogen 1

2. Don't use rifampin as monotherapy or adjunctive therapy for skin infections 1

3. Don't forget incision and drainage—for any drainable abscess, I&D is PRIMARY treatment; antibiotics are adjunctive 1, 6

4. Don't prescribe antibiotics for simple abscesses after adequate I&D unless patient has: severe/extensive disease, systemic illness, immunosuppression, extremes of age, difficult-to-drain location (face/hand/genitalia), or failed I&D alone 1

5. Check local antibiograms—MRSA resistance patterns vary significantly by region; clindamycin resistance >10% may warrant alternative choices 1

When Oral Therapy is Insufficient

Refer or hospitalize if 2, 1:

• Deep abscess requiring surgical drainage
• Extensive bone/joint involvement
• Crepitus or gas in tissues
• Necrotizing infection suspected
• Failed outpatient therapy
• Systemic toxicity/sepsis
• Immunocompromised host with severe infection

Evidence Quality Note

The IDSA guidelines 1 provide the strongest and most recent evidence (2011) with Grade A recommendations based on multiple clinical trials. The recommendation for clindamycin has A-I evidence (highest quality), while TMP-SMX and tetracyclines have A-II evidence. A 2017 RCT 7 with 786 patients confirmed that both clindamycin and TMP-SMX significantly improved cure rates (83.1% and 81.7% respectively) compared to placebo (68.9%) when added to I&D for abscesses ≤5 cm, though clindamycin had more adverse events (21.9% vs 11.1%).